Clinical Trial: The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Brief Summary: The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.

Detailed Summary: F-18 florbetapir is currently used for the early detection of brain amyloid (Alzheimer's disease). The hypothesis is that F-18 florbetapir will detect amyloid deposition in myocardium prior to current non-invasive diagnostic measures, particular electrocardiography with strain and technetium pyrophosphate scintigraphy. The investigators intend to use F-18 florbetapir and assess its correlation between standard non-invasive diagnostic modalities.
Sponsor: Wael Jaber

Current Primary Outcome: Frequency of positive studies as determined by the tracer uptake by the heart. [ Time Frame: 1 month ]

Number of participants with extracardiac transthyretin (TTR) or Light Chain (AL) amyloid deposits with positive Florbetapir-18 PET scan


Original Primary Outcome:

  • Frequency of positive studies as determined by the tracer uptake by the heart. [ Time Frame: 1 month ]
    Number of participants with extracardiac transthyretin (TTR) or Light Chain (AL) amyloid deposits with positive Florbetapir-18 PET scan
  • Correlation of F-18 florbetapir PET scan with TcPYP scan. [ Time Frame: 1 month ]
    Correlation of TcPYP nuclear scintigraphy with F-18 florbetapir PET scan in patients with ATTR


Current Secondary Outcome:

  • Development of clinical symptoms of cardiac amyloidosis by conventional cardiac testing. [ Time Frame: 1 year ]
    To determine that if florbetapir F18 scan can be used to detect the early amyloid involvement of the heart
  • Correlation of F-18 florbetapir PET scan with TcPYP scan. [ Time Frame: 1 month ]
    Correlation of TcPYP nuclear scintigraphy with F-18 florbetapir PET scan in patients with ATTR


Original Secondary Outcome: Development of clinical symptoms of cardiac amyloidosis by conventional cardiac testing. [ Time Frame: 1 year ]

To determine that if florbetapir F18 scan can be used to detect the early amyloid involvement of the heart


Information By: The Cleveland Clinic

Dates:
Date Received: January 31, 2017
Date Started: January 2017
Date Completion: December 2017
Last Updated: April 17, 2017
Last Verified: April 2017